지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 1,243 - 1,252 (10page)
이용수
초록· 키워드
오류제보하기
Purpose The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study).
Materials and Methods Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients.
Results More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child- Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatment-emergent adverse events was similar in both Child-Pugh A (85.4%) and Child-Pugh B (84.8%) patients.
Conclusion Sorafenib was well tolerated by Korean HCC patients in clinical settings, and the safety profile did not appear to differ by Child-Pugh status. Survival benefit in Korean patients was in line with that of a previous pivotal phase III trial (SHARP).
목차
등록된 정보가 없습니다.
참고문헌 (16)
참고문헌 신청
Kim DY / 2012 / Epidemiology and surveillance of hepatocellular carcinoma / Liver Cancer 1:2~14
Ferlay J / 2010 / Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008 / Int J Cancer 127:2893~2917
Bolondi L / 2012 / Heterogeneity of patients with intermediate(BCLC B)hepatocellular carcinoma : proposal for a subclassification to facilitate treatment decisions / Semin Liver Dis 32:348~359
Jeng KS / 2015 / Heterogeneity of hepatocellular carcinoma contributes to cancer progression / Crit Rev Oncol Hematol 94:337~347
Han KH / 2013 / Survival of hepatocellular carcinoma patients may be impro-ved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study / J Clin Gastroenterol 47:538~544
Ferlay J / 2010 / Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008 / Int J Cancer 127:2893~2917
Bolondi L / 2012 / Heterogeneity of patients with intermediate(BCLC B)hepatocellular carcinoma : proposal for a subclassification to facilitate treatment decisions / Semin Liver Dis 32:348~359
Jeng KS / 2015 / Heterogeneity of hepatocellular carcinoma contributes to cancer progression / Crit Rev Oncol Hematol 94:337~347
Han KH / 2013 / Survival of hepatocellular carcinoma patients may be impro-ved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study / J Clin Gastroenterol 47:538~544
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
Clinical and Molecular Hepatology
2015 .01
-
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib
Yonsei Medical Journal
2017 .01
-
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
Clinical and Molecular Hepatology
2020 .01
-
Usefulness of sarcopenia in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment
대한외과학회 학술대회 초록집
2019 .10
-
Tumor lysis syndrome following sorafenib treatment in hepatocellular carcinoma
영남의대학술지
2015 .01
-
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
Journal of Liver Cancer
2021 .09
-
Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review
Clinical and Molecular Hepatology
2017 .01
-
An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib
Annals of Hepato-Biliary-Pancreatic Surgery
2015 .02
-
Effectiveness and safety of sorafenib 400 mg vs. 800 mg initial dose on survival in patients with advanced and intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
Journal of Korean Medical Science
2018 .01
-
A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases
Journal of Liver Cancer
2022 .03
-
HCC 재발환자에서 sorafenib 적용 증례
WITH CAP(COMPANION ANIMAL PRACTICE)
2021 .04
-
The strategy for the treatment of hepatocellular carcinoma
대한동의병리학회 학술대회논문집
2015 .10
-
폐전이를 보인 단일결절형 거대 간세포암종 환자에서 순차적인 경동맥화학색전술과 Sorafenib으로 완전관해를 보인 1예
Journal of Liver Cancer
2016 .01
-
Sensitization of hepatocellular carcinoma cells against sorafenib treatment with autophagy regulation
한국실험동물학회 학술발표대회 논문집
2019 .07
-
Effects of the mixed formulation of sorafenib and blue honeysuckle on the pharmacokinetics profiles of sorafenib
대한예방한의학회지
2019 .01
-
Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath?
Radiation oncology journal : ROJ
2017 .01
-
Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea
Gut and Liver
2024 .01
-
Secondary adrenal insufficiency caused by sorafenib administration in a patient with hepatocellular carcinoma
영남의대학술지
2016 .01
-
A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
Clinical and Molecular Hepatology
2020 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0